Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity

dc.creatorTorres, Letícia de Menezes
dc.creatorAlves, Jessica Rafaela dos Santos
dc.creatorTang, Michaelis Loren
dc.creatorSanchez, Bruno Antônio Marinho
dc.creatorSousa, Taís Nóbrega de
dc.creatorFontes, Cor Jésus Fernandes
dc.creatorNogueira, Paulo Afonso
dc.creatorRocha, Roberto Sena
dc.creatorBrito, Cristiana Ferreira Alves de
dc.creatorAdams, John H.
dc.creatorKano, Flora Satiko
dc.creatorCarvalho, Luzia Helena
dc.date2015-02-25T18:55:01Z
dc.date2015-02-25T18:55:01Z
dc.date2014
dc.date.accessioned2023-09-26T20:14:31Z
dc.date.available2023-09-26T20:14:31Z
dc.identifierTORRES, Letı́cia Menezes et al. Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity. PLoS One. V. 9, n. 7 p. e93782, 2014
dc.identifier1932-6203
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/9544
dc.identifier10.1371/journal.pone.0093782
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8852245
dc.descriptionThe Plasmodium vivax Duffy binding protein (PvDBP) and its erythrocytic receptor, the Duffy antigen receptor for chemokines (DARC), are involved in the major P. vivax erythrocyte invasion pathway. An open cohort study to analyze DARC genotypes and their relationship to PvDBP immune responses was carried out in 620 volunteers in an agricultural settlement of the Brazilian Amazon. Three cross-sectional surveys were conducted at 6-month intervals, comprising 395, 410, and 407 subjects, respectively. The incidence rates of P. vivax infection was 2.32 malaria episodes per 100 person-months under survey (95% confidence interval [CI] of 1.92-2.80/100 person-month) and, of P. falciparum, 0.04 per 100 person-months (95% CI of 0.007-0.14/100 person-month). The distribution of DARC genotypes was consistent with the heterogeneous ethnic origins of the Amazon population, with a predominance of non-silent DARC alleles: FY*A > FY*B. The 12-month follow-up study demonstrated no association between DARC genotypes and total IgG antibodies as measured by ELISA targeting PvDBP (region II, DBPII or regions II-IV, DBPII-IV). The naturally acquired DBPII specific binding inhibitory antibodies (BIAbs) tended to be more frequent in heterozygous individuals carrying a DARC-silent allele (FY*BES). These results provide evidence that DARC polymorphisms may influence the naturally acquired inhibitory anti-Duffy binding protein II immunity.
dc.formatapplication/pdf
dc.languageeng
dc.publisherPublic Library of Science
dc.rightsopen access
dc.subjectAntigens, Protozoan/immunology
dc.subjectCross-Sectional Studies
dc.subjectDuffy Blood-Group System/genetics
dc.subjectPolymorphism/Genetic
dc.subjectProtozoan Proteins/immunology
dc.subjectMalaria, Vivax/genetics
dc.subjectMalaria, Vivax/immunology
dc.titleDuffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity
dc.typeArticle


Este ítem pertenece a la siguiente institución